Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2017 Jun 12;77(11):1261. doi: 10.1007/s40265-017-0772-7

Erratum to: JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects

Shubhasree Banerjee 1,✉, Ann Biehl 2, Massimo Gadina 3, Sarfaraz Hasni 4, Daniella M Schwartz 5
PMCID: PMC7608299  PMID: 28608167

Erratum to: Drugs (2017) 77:521–546 DOI 10.1007/s40265-017-0701-9

Page 539, Table 6 Janus Kinase Inhibitors in preclinical and early clinical development

The first row/entry which currently reads:

Drug Specificity Clinical Status Diseases
OP0155 [199] JAK3 Preclinical Rat adjuvant induced arthritis
Open in a new tab

Should read:

Drug Specificity Clinical Status Diseases
PF-06651600 [199] JAK3 Phase 2 (ClinicalTrials.gov. NCT02969044, NCT02974868, NCT02958865) Rheumatoid arthritis, alopecia areata, ulcerative colitis
Open in a new tab

Footnotes

The online version of the original article can be found under doi:10.1007/s40265-017-0701-9.

Articles from Drugs are provided here courtesy of Nature Publishing Group

RESOURCES